Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Gossamer Bio, Inc.

Get SEC filing alerts via email and in your feed for Gossamer Bio, Inc.

GOSS

Gossamer Bio, Inc.

About Gossamer Bio, Inc.

Gossamer Bio, Inc. is a biopharmaceutical company focused on developing therapies for pulmonary hypertension, including PAH and PH-ILD. Its lead candidate, seralutinib, is an inhaled kinase inhibitor targeting pathways involved in vascular remodeling. The company advances clinical trials, collaborates globally, and aims to provide innovative, targeted treatments for high unmet medical needs in rare pulmonary diseases.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Gossamer Bio, Inc.

1
1
Gossamer Bio, Inc. Gossamer Bio Reports $16.96M Revenue and $46.66M Net Loss in Q1 2026

Via official filing (AI summary) | 24 days ago | 0 comments

2
1
Gossamer Bio, Inc. Gossamer Bio Reports 58% Revenue Decline and $170.4 Million Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Gossamer Bio, Inc. Gossamer Bio Reports 40% Revenue Increase in Q3 2025, Net Loss of $48.2 Million

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Gossamer Bio, Inc. Gossamer Bio Reports Significant Revenue Decline and Increased Losses in Latest Quarter

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Gossamer Bio, Inc. Gossamer Bio Reports $9.9 Million Revenue in Q1 2025, Net Loss Decreases to $36.6 Million

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Gossamer Bio, Inc. Gossamer Bio Reports $56.5 Million Net Loss for 2024, Revenue Driven by Collaboration with Chiesi

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Gossamer Bio, Inc. Gossamer Bio Reports Significant Revenue Growth and Improved Operating Performance in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments